Tiffany Traina, MD, FASCO

Panelists discuss how the expanding volume of clinical data—both positive and negative—is increasing treatment complexity while reinforcing the need for individualized, patient-centered decision-making.

Panelists discuss how toxicity monitoring and quality-of-life considerations must be adapted as potent therapies move into earlier-line and curative-intent settings.

Panelists discuss how identifying high-risk subgroups enables more precise selection of maintenance therapies that maximize progression-free survival while accounting for biomarker differences.

Panelists discuss how emerging neoadjuvant and adjuvant data in HER2-positive breast cancer are challenging traditional standards and supporting earlier use of highly effective agents.

Panelists discuss how results from antibody-drug conjugate trials, including those that fail primary endpoints, provide critical insights for refining sequencing strategies in hormone receptor–positive disease.

Panelists discuss how post-CDK4/6 endocrine strategies increasingly rely on molecular profiling to guide therapy selection and optimize benefit in resistant disease.

Panelists discuss how data from recent ESR1-mutant disease trials are influencing interpretation of survival end points, regulatory expectations, and real-world adoption of oral SERDs.

Panelists discuss how rapidly evolving guidelines are reshaping treatment pathways by preserving endocrine therapy as a backbone while introducing earlier use of combination regimens and ADCs.

Panelists discuss how sequencing targeted therapies after CDK4/6 inhibitors differs for patients with actionable mutations versus those without, incorporating evidence for rechallenge and combination strategies.

Panelists discuss how integrating both tissue and liquid genomic testing at diagnosis and progression improves detection of tumor heterogeneity and informs personalized treatment decisions in metastatic breast cancer.